Summary The investigative anti-tumour agent 5,6-dimethylxanthenonone-4-acetic acid (DMXAA, NSC 640488), developed in this laboratory as an improved analogue of flavone acetic acid (FAA, NSC 347512), is currently in clinical trial. The ability of DMXAA to up-regulate tumour necrosis factor (TNF) mRNA and protein synthesis in cultured human peripheral blood leucocytes (HPBLs) has been investigated and compared with that of flavone acetic acid (FAA) and of bacterial lipopolysaccharide (LPS). Human peripheral blood leucocytes were isolated from buffy coats obtained from a blood transfusion centre and also from blood samples from laboratory volunteers. At a concentration of 400 gg ml-' and an incubation time of 2 h, DMXAA up-regulated mRNA synthesis in six of eight individuals tested, as measured by Northern blotting. The degree of up-regulation varied in different individuals from one to nine times that of control levels. In contrast, FAA caused no induction above that of control levels and in some cases suppressed expression relative to controls, extending previous data that DMXAA but not FAA up-regulates TNF mRNA in the human HL-60 tumour cell line. At the same concentration but with longer incubation times (6-12 h), DMXAA induced increases in TNF protein in 11 of 15 samples of HPBLs from buffy coats and also in 11 of 15 samples of HPBLs from volunteers, as measured by cytotoxicity assays with L929 cells. FAA caused no increase in TNF protein, while LPS induced TNF to approximately 20-fold higher levels than did DMXAA. Considerable heterogeneity of response was observed with both sources of HPBLs, and there was little or no correlation between the extent of TNF induction by DMXAA and LPS in individual samples. In vitro analysis of the response of human peripheral blood leucocytes to DMXAA may be a useful test in clinical trials of agents such as DMXAA.
DMXAA (5,6-dimethylxanthenone-4-acetic acid; NSC 640488), a novel biological response modifier, was developed in this laboratory as an improved analogue of FAA (flavone acetic acid) (Rewcastle et al, 1991) . While FAA shows excellent activity against a range of murine solid tumours (Plowman et al, 1986; O'Dwyer et al, 1987) , it has no clinical activity as a single agent (Kerr and Kaye, 1989) . FAA and DMXAA have little direct in vitro cytotoxicity and appear to mediate their anti-tumour activity through host immune modulation (Ching and Baguley, 1987; Finlay et al, 1988; Baguley et al, 1989) . DMXAA is 12 times more dose potent than FAA in its immune-stimulating effects and antitumour activity in mice (Rewcastle et al, 199 1; Philpott et al, 1995) . However, the key question with this class of agents is whether DMXAA can act more efficiently than FAA against human cells.
TNF (tumour necrosis factor-a) appears to play a pivotal role in the anti-tumour effects of DMXAA and FAA in mice. Among analogues of DMXAA tested, a strong correlation was observed between elevation of serum TNF activity and anti-tumour potential Received 10 Feburary 1997 Revised 20 May 1997 Accepted 29 May 1997 Correspondence to: L-M Ching (Philpott et al, 1995) . Scheduling of DMXAA in two doses given 3 days apart led to a ninefold increase in serum TNF production and an improved anti-tumour effect compared with that obtained with a single dose (Philpott et al, 1995) . Antibodies to TNF inhibit FAAinduced tumour vascular collapse (Mahadevan et al, 1990 ) and reduce its anti-tumour effect (Pratesi et al, 1990) . These observations suggest that TNF induction could be a useful indicator of the activity by this class of agents.
FAA is an efficient inducer of mRNA for IFN (interferon) and TNF, both in vivo and in cultured murine splenocytes and peripheral blood leucocytes. Although it also induces IFN secretion in cultured mouse lymphocytes, it does not up-regulate cytokine gene expression or protein secretion in cultured human peripheral blood leucocytes (HPBLs) (Futami et al, 1991) . DMXAA up-regulates TNF mRNA in the human HL-60 and in murine J774 cells, while FAA induces TNF mRNA in J774 cells only . These observations suggest that an activation pathway is present in both human and murine cell systems but that only DMXAA is able to stimulate the pathway efficiently in human cells. In this report, we have extended our previous studies to examine the production of TNF in cultures of HPBLs in response to DMXAA and FAA. We have also compared responses to these agents with that to LPS (lipopolysaccharide, endotoxin), a classical inducer of TNF synthesis (Carswell et al, 1975 (Rewcastle et al, 1991) , was dissolved in
The culture medium was o-minimal essential medium (Gibco, culture medium. Solutions were prepared freshly for each experiGrand Island, NY, USA) supplemented with 10% fetal calf serum, ment and protected from light (Rewcastle et al, 1990 Approval for the use of HPBLs in this project was obtained from the North Health Ethics Committee, Auckland, New Zealand. Partly purified buffy coats from healthy donors (identified by sex and age), which had been stored in CPD buffer (0.1 M sodium citrate, 0.015 M monosodium phosphate, 0.071 M dextrose; Baxter Pharmaceuticals, Auckland, New Zealand) as an anticoagulant, were purchased from the regional blood transfusion centre. They were diluted threefold with a-minimal essential medium before use. Whole blood was also taken from healthy volunteers in the laboratory. HPBLs were isolated from the above sources by fractionation on Ficoll-Paque (Pharmacia, Uppsala, Sweden) gradients and cultured overnight at 107 cells ml-' at 37°C in an atmosphere of 5% carbon dioxide in air. FAA, DMXAA or LPS were then added to culture and, after further incubation for various times, the supernatants were harvested for TNF determination. In some experiments, Trizol (Gibco BRL, Life Technologies, Gaithersburg, MD, USA) was added to the cells after the supernatant had been removed, and mRNA was extracted according to manufacturer's instructions.
TNF assay L929 cells (3x104 in 100 ,l of culture medium) were placed in each well of flat-bottomed 96-well plates and allowed to adhere overnight. Actinomycin D (Merck, Sharpe and Dohme, Granville, NSW, Australia) was added to 16 gg ml' (i.e. to provide a final concentration of 5.3 jig ml-'). Samples were added to the first row of wells to give a total volume of 300 gl and sequential threefold dilutions of the sample were then performed over the length of the plates. Plates were then incubated for 24 h at 370C, MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide; 500 jg ml-'] was added and the cultures were incubated for 1 h to allow dark-blue crystals to appear. Supernatants were removed and (400 9g ml-'). The culture supernatants were harvested at different times and were assayed for TNF activity; mean values were plotted. Vertical lines represent standard errors of the mean 100 ,ul of dimethyl sulphoxide (Prolabo, Paris, France) was added to solubilize the crystals. Absorbance at 570 nm was measured using an automatic ELISA reader (MR 600, Dynatech, Alexandria, VA, USA). Dose-response curves were constructed, and the dilutions that gave a 50% reduction in staining intensity were determined (Philpott et al, 1995) . One unit of TNF was defined by this assay as the amount reducing staining intensity of L929 cells by 50%.
Northern blot analysis of mRNA Total cellular RNA was isolated using either Trizol or a single-step acid-phenol-chloroform extraction procedure as previously described (Chomczynski and Sacchi, 1987) . RNA was applied (15 jig per lane) and was separated by denaturing gel electrophoresis on a 1% agarose-17% formaldehyde gel. RNA was then transferred to a nylon membrane (Hybond N+) by capillary action using 20 x SSC (SSC: 0.15 M sodium chloride, 0.015 M sodium citrate), and the RNA was then UV cross-linked and baked on to the membrane. Prehybridization (1 h) and hybridization (overnight) were carried out at 420C in 50% formamide, 0.075 M sodium chloride, 0.05 M sodium dihydrogen phosphate, 5 mM EDTA, 0.001% (w/v) polyvinyl pyrrolidone, 0.001% (w/v) bovine serum albumin (Sigma, A-4503), 0.001% (w/v) Ficoll (Sigma, F-4375), 0.01 mg ml-' herring sperm DNA and 0.5% sodium dodecyl sulphate (SDS). An 820 basepair cDNA sequence (Genentech, San Francisco, CA, USA) that encodes for the human TNF protein was labelled with 32p using dCTP (3000 Ci mmol-', NEN, Boston, MA, USA) and a random-primed DNA labelling kit (Boehringer Mannheim, Germany). Labelled probe was separated from free radiolabelled nucleotide by centrifugation through a G-25 Sephadex column and was added to the hybridization buffer to 106 c.p.m. ml-'. After hybridization, filters were washed in 2 x SSC and 0.1% SDS for 30 min at 68°C and in 1 x SSC and 0.1% SDS for 20 min at 68'C. The filters were blotted dry and exposed to radiographic film (Kodak XAR-5) at -700C with intensifying screens for 10 days. The mRNA signal was quantitated by laser densitometric scanning. Loading of the 28S and 18S RNA bands in different lanes was visualized under ultraviolet light after staining with ethidium bromide.
British Journal of Cancer (1997) were cultured with DMXAA (400 9g ml-'), FAA (400 9g ml-'), LPS (5 9g ml-') or without any stimulation (controls). Supernatants were harvested after 6 h and were assayed for TNF activity. TNF units were defined using the L929 assay RESULTS
Induction of TNF mRNA in HPBLs
HPBLs from eight blood donors were exposed for 2 h to DMXAA or FAA at 200 and 400 jg ml-' with exposure time and drug concentrations based on optimal conditions in previous studies with myeloid cell lines . Cellular mRNA was extracted and assayed for TNF mRNA. Greater induction was obtained at 400 jg ml' for HPBLs (Figure 1 ). The amounts of TNF mRNA obtained in the HPBLs from the eight individuals in response to DMXAA and FAA (400 jig ml-') were compared as ratios with the amount of TNF mRNA in untreated control cultures for each individual (Figure 2 We also examined the dose-response of HPBLs to DMXAA, measuring TNF activity after 8 h for blood donors T, U and V, and after 12 h for blood donors A2, C2 and D2 ( Figure 5 ). Although British Journal of Cancer (1997) 76(12) In a further experiment to determine the variability of response in repeat samples, four samples were taken from each of eight donors over a period of 3 months. In this experiment, CPD was used as an anticoagulant and each sample was exposed to DMXAA (400 jig ml-') for 12 h before analysis of TNF activity.
Variability was observed both between individual donors and between consecutive samples from the same donor, with no significant difference between individuals except for one, which produced a consistently negative TNF response ( Figure 6 ).
DISCUSSION
We have shown that DMXAA, in contrast to FAA, can induce TNF production in cultured HPBLs, thus overcoming the species specificity that appears to exist for FAA. The results extend previous observations that TNF mRNA is induced by DMXAA but not by FAA in the human myeloid HL-60 line and that TNF mRNA is not induced by FAA in HPBLs (Futami et al, 1991) .
The lower concentration of DMXAA used for the in vitro induction of TNF mRNA in HPBLs (200,g ml-'; 650 gM) is similar to the in vivo plasma concentration of DMXAA (600 jM) at the maximum therapeutic dose in mice (McKeage et al, 1991) . Moreover, the total in vitro drug exposure under the optimal conditions (400 jg ml for 2 h; 2600 jimol h 1-') is similar to the area under the plasma concentration vs time curve (2400 jmol h 1-1) for DMXAA at the maximum therapeutic dose in mice (McKeage et al, 1991) .
After exposure to DMXAA, secreted TNF protein begins to accumulate in HPBL culture supematants after 4 h (Figure 3 ). The levels of TNF obtained in response to DMXAA are generally 20-fold lower than those obtained in cultures of HPBLs stimulated with LPS (Figures 3 and 6) . LPS forms complexes with LPS binding proteins (LBP) that interact with the CD-14 receptor on myeloid cells (Haziot et al, 1993) . The high sensitivity of the CD-14 receptor system (Lee et al, 1992) may account for the high efficiency of LPS in stimulating TNF production. Although the receptor for DMXAA has not been identified, DMXAA appears to activate cells by a pathway that is not identical to the one used by LPS (Perera et al, 1994) . The lower amounts and slower kinetics of TNF production in response to DMXAA, compared with LPS, suggests differences in the activation pathways of the two agents. Alternatively, DMXAA and LPS may stimulate different subpopulations of cells. The cell populations in peripheral blood responding to DMXAA have not yet been characterized.
A striking observation emerging from these studies is the degree of inter-individual variation in the TNF response induced with DMXAA ( Figure 4 ). This heterogeneity is also observed at the level of mRNA up-regulation (Figure 2) , suggesting that the variability in the levels of TNF protein produced reflect individual differences in mRNA induction rather than differences in the rates of synthesis or secretion of the protein. The response to LPS is also variable between individuals (Figure 4) , consistent with previous studies (Molvig et al, 1988; Bruin, 1994) .
The gene encoding TNF maps within the region encoding the major histocompatibility gene products on chromosome 6 (Spies et al, 1986) . High TNF production in response to LPS has been shown to be associated with HLA-DR3, HLA-B8 and HLA-A1 haplotypes (Jacob et al, 1990) and low TNF production with HLA-DR2 and DQwl haplotypes (Bendtzen et al, 1988; Jacob et al, 1990) , indicating that TNF production in response to LPS is HLA linked. Several multiallelic polymorphisms within the major histocompatibility complex are in very close physical linkage to the TNF locus (Drouet et al, 1991) . In addition, polymorphism in the TNF promoter has been described (Manus et al, 1996) . These polymorphisms within the regulatory elements of the TNF gene or in the microsatellite regions of the major histocompatibility complex could be a basis for the HLA-linked variability in TNF production between individuals.
It is clear from the present experiments (Figure 4 ) that individual responsiveness of HPBLs to DMXAA and LPS are not highly correlated, suggesting that the response to DMXAA is not under the same genetic control from the HLA locus. Apart from genetic predisposition, inter-individual differences in TNF production can also be caused by hormonal regulation. In humans, LPS responsiveness in repeated testing is stable in men and postmenopausal women but fluctuates in premenopausal women, suggesting regulation by sex hormones (Jacob et al, 1990) . We have shown in mice that the anti-tumour efficacy of DMXAA is modulated by exogenously administered cortisone, suggesting that the response to DMXAA may depend on circulating corticosteroids (Ching et al, 1993) . None of the donors used for this study were on corticosteroid medication, and further work is required to test the hypothesis that steroid hormones regulate the DMXAA responsiveness of HPBLs.
In conclusion, it is pertinent to ask whether the in vitro responsiveness of HPBLs to DMXAA may be an indication of individual in vivo responsiveness to DMXAA therapy. It is known that the in vivo responsiveness of individuals to LPS correlates with the in vitro ability of their peripheral blood monocytes to secrete TNF in response to LPS (Bruin, 1994) . The demonstration of TNF production by HPBLs cultured with DMXAA is of particular relevance to the clinical trials of DMXAA and raises the question of whether such assays should be used in monitoring the course of treatment. The heterogeneity of the responsiveness to DMXAA among individuals, demonstrated here, emphasizes the need to determine the factors regulating the response of patients selected for DMXAA therapy.
